. 2021 Feb 4;777:145471. doi: 10.1016/j.gene.2021.145471

Table 1.

Clinical trial completed project about Covid-19 (12/24/2020 - ClinicalTrials.gov).

ClinicalTrials.gov ID:	Phase	participants	region of cell	center (country)	Allocation Model	Intervention
NCT04288102	II	100	Human Umbilical Cord-derived Mesenchymal Stem Cells	Beijing 302 Hospital (China)	Randomized, double-blind, placebo-controlled study (Parallel Assignment)	3 does of UC-MSCs (4x10⁷ cells per time) intravenously at Day 0, Day 3, Day 6
NCT04473170	I/II	146	Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)	Abu Dhabi Stem Cells Center (UAE)	Randomized (Parallel Assignment)	N/A
NCT04355728	I/II	24	Human Umbilical Cord-derived Mesenchymal Stem Cells	University of Miami (US)	Randomized, double-blind, placebo-controlled study (Parallel Assignment)	UC-MSC will be administered at 100x10⁶ cells/infusion administered intravenously
NCT04573270	I	40	Human Umbilical Cord-derived Mesenchymal Stem Cells	Thomas Advanced Medical LLC (US)	randomized, double-blind, placebo-controlled, multi-arm, multi-site (Single Group Assignment)	Single intravenous injections of mesenchymal stem cells derived from human umbilical chords
NCT04492501	Not Applicable	600	Bone Marrow MSC	UNICEF (Pakistan)	Non-Randomized, open label (Factorial Assignment)	Single Dose of 2x10⁶ cells/kg
NCT04276987	I	24	MSCs-derived exosomes	Ruijin Hospital (China)	N/A (Single Group Assignment)	5 times aerosol inhalation of MSCs-derived exosomes (2x10⁸ nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5).
NCT04491240	I/II	30	MSCs-derived exosomes	Samara Regional Medical Center Dinasty (Russia)	Randomized, double-blind, placebo-controlled study (Parallel Assignment)	Twice a day during 10 days inhalation of 3 ml special solution contained 0.5-2x10¹⁰ of nanoparticles (exosomes)